Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The intrinsic mitochondrial apoptotic pathway acts through two core pro-apoptotic proteins Bax (Bcl2-associated X protein) and Bak (Bcl2-antagonist/killer 1). Although Bax and Bak seem to have redundant roles in apoptosis, accumulating evidence also suggests that they might not be interchangeable under certain conditions, at least in some human cell lines. Here we report the generation of Bak knockout as well as BaxBak double knockout HCT116 human colon carcinoma cells. We show that Bak is dispensable for apoptosis induced by a variety of stimuli including ABT-737 but not for fluorouracil-induced apoptosis. In addition, Bax deficiency only provides partial protection against camptothecin and cisplatin-induced apoptosis and no protection against killing by Puma or ABT-737 plus Noxa overexpression. Moreover, Bak is activated normally in response to many chemotherapeutic drugs in the presence of Bax, but remains kept in check by Mcl-1 in the absence of Bax. Our data suggest that Bax and Bak are functionally redundant, but they are counteracted by distinct anti-apoptotic Bcl-2 family proteins in different species.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, BAK BAX double knock-out (DKO) cells were completely resistant to the modest pro-apoptotic effects of selumetinib or the more striking response to combined selumetinib + AZD5991 (Fig. 5h).”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [38]
In the citing paper
“BAK knock-out (KO) cells showed no apoptotic defect in response to either selumetinib or combination with AZD5991 (Fig. 5h), whereas cells lacking BAX exhibited a 60% reduction in apoptosis.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [38]
In the citing paper
“BAK knock-out (KO) cells showed no apoptotic defect in response to either selumetinib or combination with AZD5991 (Fig. 5h), whereas cells lacking BAX exhibited a 60% reduction in apoptosis.”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489
Otera, H., Wang, C., Cleland, M. M., Setoguchi, K., Yokota, S., Youle, R. J., & Mihara, K. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201007152 · Cited by 1,110 · cited 2×
“Tomake gene-targeting construct (KO), two 1-kb sequences flanking exon 5 of the human Bak gene were PCR amplified from HCT 116 genomic DNA and cloned into targeting vector as described, so is the rest of gene-targeting procedures (Otera et al., 2010).”
MethodSelf-citationHierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies
Kim, H., Rafiuddin-Shah, M., Tu, H.-C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1499 · Cited by 874 · cited 9×
“The three Bax/Bak direct activators (Kim et al., 2006), Bim, Bid and Puma, exhibited differential killing ability in Bax / and Bax / Bak / DKO cells.”
BackgroundResultInfluentialRole of BAX in the Apoptotic Response to Anticancer Agents
Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., & Vogelstein, B. (2000) · Science · doi:10.1126/science.290.5493.989 · Cited by 863 · cited 8×
“Bax seems to be the key pro-apoptotic factor in human cells as Bax / HCT116 cells are extremely resistant to apoptosis (Zhang et al., 2000) and Bak appears to be dispensable for apoptosis based on gene-knockdown studies (Cartron et al., 2003; Chandra et al., 2005; Gillissen et al., 2007, 2010).”
BackgroundMethodInfluential
Cited by
Mitochondrial apoptosis: killing cancer using the enemy within
Lopez, J., & Tait, S. W. G. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.85 · Cited by 784
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
BCL-2 family isoforms in apoptosis and cancer
Warren, C. F. A., Wong-Brown, M. W., & Bowden, N. A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1407-6 · Cited by 700
BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation
Llambi, F., Wang, Y.-M., Victor, B., Yang, M., Schneider, D. M., Gingras, S., Parsons, M. J., Zheng, J. H., Brown, S. A., Pelletier, S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.026 · Cited by 261
Sublethal cytochrome c release generates drug-tolerant persister cells
Kalkavan, H., Chen, M. J., Crawford, J. C., Quarato, G., Fitzgerald, P., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 255
Metadata
- Authors
- Wang, C., & Youle, R. J.
- Venue
- Oncogene
- Published
- 2011-11-07
- Volume
- 31
- Issue
- 26
- Pages
- 3177-3189
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2044388181
- Cited by
- 113
- References
- 5
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.